Covalent Development
Covalent Development facilite le développement de votre portefeuille clients et de votre chiffre d'affaires en Amérique du Nord. Nous sommes spécialisés dans la vente de services complexes et innovants à l'Industrie Pharmaceutique et Cosmétique.
Based in Central New Jersey, Covalent Development offers to develop US business activities of Biotech companies.
The state of New Jersey is home to more than 300 biotechnology companies and 20 pharmaceutical and medical technology firms (17 out of the world’s top 20 have major facilities in the state). This incredible concentration offers extraordinary opportunities to develop your business.
New York, Boston, Washington DC, North Carolina and Philadelphia are close and there is only 3 hours of time difference with West Coast. It makes things easier to reach your prospects and clients!
----
Basée dans le centre du New Jersey, Covalent Development propose de développer vos activités aux Etats-Unis.
L'état du New Jersey héberge plus de 300 entreprises de biotechnologie ainsi que 20 sociétés pharmaceutiques et médicales (17 du top 20 sont implantées dans l'état). C'est une localisation idéale pour développer votre business.
New York, Boston, Washington DC, la Caroline du Nord et Philadelphia sont proches et il n'y a que 3 heures de décalage horaire avec la côte ouest. De quoi faciliter les échanges avec vos prospects et clients !
Mr Anselmo Rivera
Head of Business DevelopmentCUNY
CUNY is home to more than 100 research centers, institutes and consortia, which provide research opportunities for faculty and students, employment, internships, and special events. These centers focus their efforts on a wide range of areas, including aging, applied sciences, corporate integrity, transportation systems, ethnic studies, performing arts, sustainable energy and urban studies, to name a few.
Many institutions reflect CUNY’s support of state-of-the-art education and research, such as the Institute for Ultrafast Spectroscopy and Lasers. Others exemplify the University’s commitment to service and historic preservation, including the Institute for Criminal Justice Ethics at John Jay College and the Gotham Center for New York City History, founded by Pulitzer Prize-winning historian Mike Wallace.
Mr THEODORE BROWN
ExecutiveCUNY Institute CoSSMO
Our mission is to identify potential projects and participants across CUNY and in the community at large, to help members identify sources of funding and to prepare grant applications, to facilitate the execution of the projects, providing advice, space, and computer facilities, to create research programs by aggregating multiple projects with common defining factors (such programs will promote interactions and networking that will increase the value of the research activities with respect to the contribution of individual projects), to manage program projects with core competencies, and to establish collaborations outside CUNY (national and international)
Professor Felisa Vazquez-Abad
Professor and Executive DirectorCUNY-CITY COLLEGE | the Advanced Vein Visualization, AVV-1
The Advanced Vein Visualization instrument is based on basic research conducted and patented by Robert Alfano and Stavros Demos at the Institute for Ultrafast Spectroscopy and Lasers (IUSL) of The City College of New York (CCNY). Their research was assisted by Michele Alfano-Berwanger
Dr MOHAMMAD ALRUBAIEE
RACushman & Wakefield
Cushman & Wakefield is a global leader in commercial real estate services, helping clients transform the way people work, shop, and live. The firm’s 43,000 employees in more than 60 countries provides deep local and global insights that create significant value for occupiers and investors around the world.
Spécialisationsagency leasing, global occupier services, asset services, investment management (branded DTZ Investors), capital markets, project & development services, facility services (branded C&W Services), tenant representation and valuation & advisory
Cydan: Orphan Drug Accelerator
Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking process enables formation of stand-alone companies and strategic partnerships.
SpecialtiesOrphan Drugs, Rare Diseases, Genetic Disorders
Ms Vered Bisker-Leib
Chief Business Officerd3 Medicine
We work with like-minded highly innovative people to develop meaningful medicines and create impactful health care solutions.
We are:
Strategic partners in global drug development- - Provide comprehensive scientific, strategic, and regulatory support to plan, manage, and execute full development programs
- - Formulate early development, clinical pharmacology and translational medicine strategies to fast-track preclinical development to POC
- - Improve decision making with an emphasis on quantitative analytics and use of modeling and simulation
- - Provide a fully capable and experienced drug development team, or individual components based on client needs
Darmiyan LLC
Darmiyan will offer a series of diagnostic tools aimed at early detection of complex brain diseases including neurodegenerative disorders. Darmiyan will get brain MRI data from human patients to elucidate the current condition, and which disease state the brain is progressing toward. The significance of Darmiyan’s innovation is invaluable potential to diagnose disease potential before severe symptoms develop. This novel insight originates with our technology to extract information not from the brain cells/ neurons, which exhibit abnormality only after extensive damage and cell death occurs, but from the immediate environment around them, which is called extracellular space (ECS). The ECS is often thought of as just intercellular “space,” but in reality it is the electrical and chemical pathway between all brain cells that plays an essential role in brain function and drug delivery.